Dr Reddys Laboratories Gains 0.98%: 2 Key Technical Signals Driving Momentum
2026-11-21 16:01:51Key Events This Week 16 Nov: Stock opens at Rs.1,380.00 with mild gains 18 Nov: Golden Cross formation signals potential bullish breakout 19 Nov: Technical momentum upgraded to bullish, stock nears 52-week high 20 Nov: Week closes at Rs.1,390.50, up 0.98% for the week Week OpenRs.1,380.00 Week Close<div class="stat-va...
Read MoreP/E at 41.7 vs Industry's 39.5: What the Data Shows for Dr Reddys Laboratories Ltd
2026-11-20 09:20:53Valuation Picture: Premium Reflects Confidence Amid Sector Norms The current P/E of 41.71 for Dr Reddys Laboratories Ltd stands slightly above the Pharmaceuticals & Biotechnology industry average of 39.53. This premium, though not excessive, suggests that the market is pricing in expectations of steady earnings growth or superior operational performance relative to peers. The valuation premium is consistent with the company’s mid-cap status and its position near a 52-week high, just 1.38% shy of Rs 1414.4. However, the premium also invites scrutiny — <a href="https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-...
Read More
Dr Reddys Laboratories Ltd Technical Momentum Shifts Signal Bullish Outlook
2026-11-19 08:03:32Dr Reddys Laboratories Ltd has witnessed a notable shift in its technical momentum, with key indicators signalling an upgrade from a mildly bullish to a bullish trend. This change reflects improving price dynamics and growing investor confidence in the mid-cap pharmaceutical giant, supported by robust moving averages and positive MACD and Bollinger Bands readings.
Read More
Golden Cross Confirmed: Do Dr Reddys Laboratories Ltd's Other Technical Indicators Agree?
2026-11-18 18:00:23The 50-day moving average has crossed above the 200-day moving average for Dr Reddys Laboratories Ltd, signalling a golden cross on 18 Nov 2026. While this technical event often suggests a shift towards bullish momentum, the broader technical and fundamental context must be examined to assess the signal's reliability.
Read MoreP/E at 41.38 vs Industry's 39.31: What the Data Shows for Dr Reddys Laboratories Ltd
2026-11-18 09:20:45Index Membership and Market Capitalisation Impact As a constituent of the Nifty 50, Dr Reddys Laboratories Ltd holds a pivotal role in shaping the benchmark's pharmaceutical and biotechnology representation. The company's market capitalisation stands at ₹1,15,768.64 crores, categorising it as a mid-cap stock within the broader index framework. This positioning ensures that Dr Reddys commands considerable attention from index funds and institutional investors tracking the Nifty 50, thereby influencing liquidity and trading volumes. Its proximity to the 52-week high—just 2.2% shy of ₹1,414.4—signals sustained investor confidence, despite a minor day-on-day decline of 0.07%. The stock opened at ₹1,384 and maintained this leve...
Read MoreP/E at 41.17 vs Industry's 39.33: What the Data Shows for Dr Reddys Laboratories Ltd
2026-11-17 09:21:24Valuation Picture: Premium Reflecting Market Confidence? The current P/E of 41.17 for Dr Reddys Laboratories Ltd is marginally higher than the industry average of 39.33, indicating a valuation premium of roughly 4.7%. This premium suggests that investors are willing to pay slightly more for the stock relative to its peers in Pharmaceuticals & Biotechnology. Such a premium can be interpreted as a reflection of the company’s perceived earnings quality, growth prospects, or market positioning. However, the premium is not excessive, signalling a balanced valuation stance rather than an overheated one. <a href="https://www.marketsmojo.com/stocks-analysis/dr...
Read More
Dr Reddys Laboratories Ltd is Rated Hold
2026-11-15 10:10:29Dr Reddys Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 03 Nov 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 15 November 2026, providing investors with the latest insights into the company’s performance and outlook.
Read MoreP/E at 41.35 vs Industry's 39.79: What the Data Shows for Dr Reddys Laboratories Ltd
2026-11-13 09:20:50Valuation Picture: Premium Reflecting Sector Confidence Dr Reddys Laboratories Ltd trades at a P/E of 41.35, slightly above the Pharmaceuticals & Biotechnology industry average of 39.79. This premium, though not excessive, suggests the market assigns a somewhat higher growth or quality expectation to the company relative to its peers. The sector’s average P/E reflects a broad range of valuations, with some stocks trading at steep discounts and others commanding significant premiums. The current valuation implies that investors are willing to pay a 3.9% premium for <a href="https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-...
Read MoreDr Reddys Laboratories Gains 1.56%: 2 Key Factors Driving the Mild Bullish Shift
2026-11-07 16:02:14Key Events This Week 2 Nov: Stock opens at ₹1,340.25, declines 0.74% amid Sensex rally 3 Nov: Mojo Grade upgraded to Hold; stock surges 2.22% to ₹1,370.00 4 Nov: Technical momentum shifts signal mild bullish outlook; stock edges up 0.15% 5 Nov: Stock dips 0.82% despite Sensex gaining 2.05% 6 Nov: Stock rebounds 0.76% to close at ₹1,371.20 Week Open₹1,350.20<...
Read MoreDisclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015
14-Nov-2026 | Source : BSEDisclosure under Regulation 30 of SEBI (LODR) Regulations 2015
Announcement under Regulation 30 (LODR)-Newspaper Publication
11-Nov-2026 | Source : BSECopies of newspaper publication
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
10-Nov-2026 | Source : BSEIntimation of Analyst meet
Corporate Actions
No Upcoming Board Meetings
Dr Reddys Laboratories Ltd has declared 800% dividend, ex-date: 10 Jul 26
Dr Reddys Laboratories Ltd has announced 1:5 stock split, ex-date: 28 Oct 24
Dr Reddys Laboratories Ltd has announced 1:1 bonus issue, ex-date: 28 Aug 06
No Rights history available